$NUVL

Nuvalent, Inc. (NUVL): Completion of Acquisition or Disposition of Assets

Nuvalent, Inc. (NUVL) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-3.2 3 d52896dex32.htm EX-3.2 EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BY-LAWS OF NUVALENT, INC. ARTICLE I OFFICES SECTION 1.1 REGISTERED OFFICE. The registered office shall be established and maintained at the office of Corporation Service Company, in the City of Wilmington, in

Original reporting
Published Jul 15, 2026, 1:03 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 15, 2026, 1:04 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefMergers & acquisitions
Primary signal
$NUVL
Neutral
low confidence
Mentioned
$NUVL
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$NUVLNeutralMed
01

Why it matters

Completion status reduces uncertainty about deal closing, but the provided excerpt does not include the economic terms needed to forecast earnings impact.

02

Market read

This is a corporate-action confirmation for NUVL, but the excerpt lacks deal specifics, limiting conviction on direction.

03

What to watch

Traders will need the missing 8-K exhibit details (counterparty, consideration, accounting treatment) to judge whether the completion is value-accretive or a non-core exit.

Relevance 7/10Novelty 6/10Timing: Filed today on SEC EDGAR, confirming completion of the asset transaction.

Background

The SEC filing is a Form 8-K with Item 2.01, which is used to report completion of an acquisition or disposition of assets.

Company-level read

Ticker impact

$NUVLNeutralLow confidence
Context

Nuvalent filed an 8-K stating completion of an acquisition or disposition of assets, making the corporate action directly relevant to NUVL.

Expected impact

Near-term volatility possible, but direction depends on whether the completed disposition was accretive or dilutive, which is not detailed in the provided text.

Evidence & confidence

The excerpt only identifies the 8-K items (2.01 completion of asset acquisition/disposition) without transaction terms, counterparties, or financial impact.

Market effects

Limited read-through because the excerpt provides no details on the asset type (drug, platform, facility) or sector exposure.

None indicated in the provided text.

None indicated in the provided text.

Counterpoint

Completion of an asset deal may already be priced in if the transaction was previously announced; without terms, the incremental trading signal may be small.

Key entities

  • Nuvalent, Inc.

    Company filing the 8-K and subject of the completion-of-asset-transaction disclosure.

Related articles

$GSKMedAI 8/10

GSK completes acquisition of Nuvalent, Inc

GSK said it has completed its acquisition of Nuvalent (NASDAQ: NUVL) via a tender offer. The deal adds three lung cancer assets, including zidesamtinib (NVL-520) and neladalkib (NVL-655) under FDA review, plus NVL-330 in phase I. Transaction value is about $10.6B (£8.0B), net investment about $9.4B (£7.1B).

$MRVLMed

Stocks Erase Early Gains as Chipmakers Turn Lower

US stocks pared early gains as chipmakers and software firms fell. Marvell, Qualcomm, ARM and others dropped, while ServiceNow and Salesforce also declined. Treasury yields were pressured by a $58B 3-year auction and stronger May existing home sales. In Europe, Bund and gilt yields fell; swaps price a 100% chance of a 25 bp ECB hike. UNFI slid after Q3 sales missed; Nuvalent surged on a $10.6B GSK buyout.

$MUMed

More swings for AI stocks drag Wall Street back on the roller coaster

Wall Street swung as AI-related chip and memory stocks reversed after early gains. The S&P 500 fell 0.3% (7,386.65), the Nasdaq dropped 1% (25,678.82), and the Dow rose 0.2% (50,872.11). Micron slid 1.4% after a 10% drop; it had surged 9.9% Monday. Oil eased (Brent -3% to $91.45) but AI weakness outweighed. GSK agreed to buy Nuvalent for $10.6B, sending Nuvalent up 39.3%.

$COHRMed

Benzinga

U.S. stocks fell Tuesday as rotation out of chip and AI leaders resumed: Nasdaq 100 -3.3% to ~28,437, S&P 500 -1.6% to ~7,228, Dow -0.5% to ~50,535. Oil dropped ~6% and markets priced ~50% odds of a Fed hike by October ahead of Wednesday’s CPI. Tech led declines (XLK -5.1%); SMH fell as COHR -15.2%, MRVL -12.1%, LITE -11.8%.

$GSKHighAI 9/10

GSK Strikes $10.6B Nuvalent Deal Strengthening Targeting Cancer Pipeline

GSK agreed to acquire Nuvalent for $10.6B (£8.0B) to strengthen its late-stage oncology pipeline. GSK will tender for all Nuvalent shares at $124 cash, a 40% premium; net investment is $9.4B. Nuvalent’s FDA-review candidates Zidesamtinib and Neladalkib have 2026 decision dates. Deal expected to close in Q3 2026; GSK said 2026 outlook and 70p dividend remain unchanged.

$GSKHighAI 9/10

GSK Makes Its Biggest Bet In More Than A Decade, Paying $10. 6 Billion For Cancer Drug Developer Nuvalent

GSK will acquire Nuvalent for $10.6 billion, buying all outstanding shares for $124 cash each, a 40% premium to Nuvalent’s last close of $88.49. Nuvalent shares rose about 39% in premarket. GSK expects revenue growth and accretion to sales and core operating profit from 2027, and higher core EPS from 2029, gaining lung cancer assets including zidesamtinib and neladalkib.